Hua Medicine
HKEX:2552
Intrinsic Value
Hua Medicine Ltd. provides drug discovery and development services. [ Read More ]
The intrinsic value of one Hua Medicine stock under the Base Case scenario is 2.14 HKD. Compared to the current market price of 1.59 HKD, Hua Medicine is Undervalued by 26%.
Valuation Backtest
Hua Medicine
Run backtest to discover the historical profit from buying and selling Hua Medicine stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Hua Medicine
Current Assets | 940.3m |
Cash & Short-Term Investments | 490.6m |
Receivables | 415.1m |
Other Current Assets | 34.6m |
Non-Current Assets | 181.2m |
PP&E | 139.7m |
Intangibles | 32m |
Other Non-Current Assets | 9.6m |
Current Liabilities | 188.4m |
Accounts Payable | 21m |
Accrued Liabilities | 39.8m |
Short-Term Debt | 33.9m |
Other Current Liabilities | 93.6m |
Non-Current Liabilities | 653.5m |
Long-Term Debt | 42.2m |
Other Non-Current Liabilities | 611.4m |
Earnings Waterfall
Hua Medicine
Revenue
|
17.6m
CNY
|
Cost of Revenue
|
-9.9m
CNY
|
Gross Profit
|
7.7m
CNY
|
Operating Expenses
|
-237.8m
CNY
|
Operating Income
|
-230.1m
CNY
|
Other Expenses
|
26.6m
CNY
|
Net Income
|
-203.5m
CNY
|
Free Cash Flow Analysis
Hua Medicine
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Hua Medicine's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Hua Medicine's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Hua Medicine's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Hua Medicine's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Hua Medicine
According to Wall Street analysts, the average 1-year price target for Hua Medicine is 3.59 HKD .
Shareholder Return
Price
Hua Medicine
Average Annual Return | -12.65% |
Standard Deviation of Annual Returns | 21.33% |
Max Drawdown | -84% |
Market Capitalization | 1.5B HKD |
Shares Outstanding | 978 723 296 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Hua Medicine stock under the Base Case scenario is 2.14 HKD.
Compared to the current market price of 1.59 HKD, Hua Medicine is Undervalued by 26%.